Did Guggenheim recommend buying JNJ stock?

Yes, Guggenheim reiterated a Buy rating on the stock.

When did Guggenheim update its outlook on JNJ?

The update was released on June 26, 2026.

Why did Guggenheim raise the price target?

Ahead of Q2 earnings, with positive expectations driven by the company's strong business and dividends.

Johnson & Johnson Price Target Raised to $270 by Guggenheim

Guggenheim raised its price target on Johnson & Johnson (JNJ) to $270 from $266, maintaining a Buy rating, ahead of the company's Q2 earnings report.

June 28, 2026

1 min read

Source: Insider Monkey

Key Numbers

previous price target

266

new price target

270

rating

Buy

Guggenheim raised its price target on Johnson & Johnson (NYSE:JNJ) from $266 to $270, reiterating a Buy rating, in an update on June 26 ahead of the company's Q2 earnings season.

Rating Change

Previous Price Target: $266
New Price Target: $270
Rating: Buy (reiterated)

Analyst Rationale

The analyst noted the update comes before the company's Q2 earnings release, with positive expectations driven by JNJ's strong healthcare business and stable dividend payouts.

Context

Johnson & Johnson is considered one of the best dividend stocks for passive income, recently included in Insider Monkey's list of top 10 dividend stocks. The stock currently trades below the new target, potentially offering an opportunity for income-focused investors.

Conclusion

The price target increase reflects analyst confidence in the company's future performance, but investors should watch the upcoming Q2 results for further clarity.

Frequently Asked Questions

Guggenheim raised the price target to $270 from $266.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.